Post by miamianne67 on Sept 25, 2018 23:07:42 GMT
• The FDA designates Portola Pharmaceuticals' (NASDAQ:PTLA) oral Syk/JAK inhibitor cerdulatinib an Orphan Drug for the treatment of peripheral T-cell lymphoma.
• Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
• Shares are up a fraction after hours.
So far as a stock, it's been disappointing. But this looks like very good news. Ma
• Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
• Shares are up a fraction after hours.
So far as a stock, it's been disappointing. But this looks like very good news. Ma